BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 233 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $8 | -100.0% | 67,300 | -27.3% | 0.00% | -95.2% |
| Q3 2022 | $314,000 | -1.9% | 92,634 | +9.8% | 0.02% | +31.2% |
| Q2 2022 | $320,000 | -53.4% | 84,357 | -34.9% | 0.02% | -42.9% |
| Q1 2022 | $686,000 | -74.3% | 129,536 | -61.4% | 0.03% | -61.6% |
| Q4 2021 | $2,671,000 | +15.6% | 335,776 | +33.0% | 0.07% | -2.7% |
| Q3 2021 | $2,311,000 | +311.2% | 252,553 | +107.5% | 0.08% | +341.2% |
| Q2 2021 | $562,000 | +152.0% | 121,707 | +13.1% | 0.02% | +54.5% |
| Q1 2021 | $223,000 | -50.6% | 107,600 | -58.6% | 0.01% | -15.4% |
| Q4 2020 | $451,000 | +3369.2% | 259,600 | +1004.7% | 0.01% | +1200.0% |
| Q3 2020 | $13,000 | -76.8% | 23,500 | -68.3% | 0.00% | -66.7% |
| Q2 2020 | $56,000 | +522.2% | 74,100 | +60.4% | 0.00% | +200.0% |
| Q1 2020 | $9,000 | -25.0% | 46,200 | +69.9% | 0.00% | 0.0% |
| Q4 2019 | $12,000 | – | 27,200 | +35.3% | 0.00% | – |
| Q2 2019 | $0 | -100.0% | 20,100 | -60.9% | 0.00% | -100.0% |
| Q4 2016 | $326,000 | – | 51,468 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DG Capital Management, LLC | 1,186,726 | $4,076,000 | 2.45% |
| Sarissa Capital Management LP | 4,861,000 | $16,697,000 | 1.97% |
| Ghost Tree Capital, LLC | 1,950,000 | $6,698,000 | 1.94% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,525,857 | $8,676,000 | 1.14% |
| Eversept Partners, LP | 1,143,211 | $3,926,930 | 0.87% |
| DAFNA Capital Management LLC | 749,051 | $2,573,000 | 0.84% |
| KNOTT DAVID M | 397,361 | $1,365,000 | 0.80% |
| Parkman Healthcare Partners LLC | 800,740 | $2,751,000 | 0.73% |
| ACUTA CAPITAL PARTNERS, LLC | 660,000 | $2,267,000 | 0.62% |
| Formidable Asset Management, LLC | 578,200 | $1,949,000 | 0.57% |